基于肠道微生态探讨中医药治疗非酒精性脂肪性肝病的作用机制

杨雪; 张旭; 仙晋; 谭奇纹; 于慧娟

doi:10.12449/JCH240426

基于肠道微生态探讨中医药治疗非酒精性脂肪性肝病的作用机制

DOI: 10.12449/JCH240426

杨雪¹,
张旭¹,
仙晋²,
谭奇纹²,
于慧娟^2, , ,

1.
山东中医药大学针灸推拿学院，济南 250014
2.
山东中医药大学附属医院治未病中心，济南 250014

基金项目:

山东中医药大学重点学科：中医治未病学 ;

山东中医药大学附属医院朝阳人才项目

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：杨雪、张旭负责查找文献，撰写文稿；仙晋、谭奇纹负责文章思路指导；于慧娟负责审阅文稿及最后定稿。

详细信息

通信作者:
于慧娟， huijuanyu@163.com （ORCID： 0000-0003-1180-5704）

计量
- 文章访问数: 447
- HTML全文浏览量: 155
- PDF下载量: 56
- 被引次数: 0
出版历程
- 收稿日期: 2023-09-02
- 录用日期: 2023-09-18
- 出版日期: 2024-04-25

Mechanism of action of traditional Chinese medicine in treatment of nonalcoholic fatty liver disease based on intestinal microecology

Xue YANG¹,
Xu ZHANG¹,
Jin XIAN²,
Qiwen TAN²,
Huijuan YU^{2
, ,
,}

1.
School of Acupuncture and Massage，Shandong University of Traditional Chinese Medicine，Jinan 250014，China
2.
Preventive Treatment Center，The Affiliated Hospital of Shandong University of Traditional Chinese Medicine，Jinan 250014，China

Research funding:

Key Discipline of Shandong University of Traditional Chinese Medicine： Traditional Chinese Medicine Prevention and Treatment ;

Chaoyang Talent Project of Shandong University of Traditional Chinese Medicine Affiliated Hospital

More Information

Corresponding author: YU Huijuan， huijuanyu@163.com （ORCID： 0000-0003-1180-5704）

摘要

摘要: 非酒精性脂肪性肝病（NAFLD）是一种与肥胖、胰岛素抵抗和血脂异常相关的多系统疾病，其发病机制较为复杂。肠道菌群失调与NAFLD的发病密切相关，中医药治疗可通过调节肠道菌群及其代谢产物，改善NAFLD患者的实验室指标和临床症状。本文总结了NAFLD与肠道菌群的关系、肠道菌群失调参与NAFLD的发病机制，从肠道菌群角度探讨中医药治疗改善NAFLD的可能等，以期为NAFLD的治疗拓展新的思路。
- 非酒精性脂肪性肝病 /
- 肠道菌群 /
- 中医疗法
Abstract: Nonalcoholic fatty liver disease （NAFLD） is a multisystem disease associated with obesity， insulin resistance， and dyslipidemia and has a complex pathogenesis. Studies have shown that gut microbiota dysbiosis is closely associated with the onset of NAFLD， and traditional Chinese medicine treatment can improve the laboratory markers and clinical symptoms of NAFLD patients by regulating intestinal microbiota and its metabolites. This article elaborates on the association between NAFLD and gut microbiota， the involvement of gut microbiota dysbiosis in the pathogenesis of NAFLD， and the possible mechanism of traditional Chinese medicine treatment in improving NAFLD from the perspective of gut microbiota， in order to provide new ideas for the treatment of NAFLD.
- Non-alcoholic Fatty Liver Disease /
- Gut Microbiota /
- TCM Therapy

HTML全文

表 1 疾病发展过程中肠道菌群的差异

Table 1. Differences in intestinal flora during disease development

疾病	升高		降低		参考文献
疾病	门水平	科属水平	门水平	科属水平	参考文献
单纯性脂肪肝	厚壁菌、变形杆菌、放线菌	脱硫菌	拟杆菌	阿克曼菌、瘤胃球菌科	［9］
NASH	厚壁菌门、变形杆菌	普雷沃菌属、毛螺菌科、另枝菌属、肠杆菌科	拟杆菌门（乳酸菌、瘤胃球菌）	双歧杆菌科、双歧杆菌属、拟杆菌属	［10-14］
肝硬化	变形菌门、梭菌门	肠杆菌科（属）、肠球菌科（属）、韦荣球菌属、链球菌属、梭菌属、普雷沃菌属	拟杆菌门	拟杆菌属、双歧杆菌属、瘤胃球菌属、粪球菌属	［15-19］
肝细胞癌	厚壁菌门	大肠杆菌属、肠球菌属、梭菌属、考拉杆菌属、颤螺菌属、克雷伯杆菌属、嗜血杆菌属、毛螺菌属	拟杆菌门	颤杆菌克属、粪杆菌属、粪球菌属、乳酸杆菌属、双歧杆菌属、经黏液真杆菌属	［20-24］

下载: 导出CSV

参考文献(58)

[1]	MANTOVANI A, SCORLETTI E, MOSCA A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease[J]. Metabolism, 2020, 111S: 154170. DOI: 10.1016/j.metabol.2020.154170.
[2]	XIAN YX, WENG JP, XU F. MAFLD vs. NAFLD: Shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy[J]. Chin Med J(Engl), 2020, 134( 1): 8- 19. DOI: 10.1097/CM9.0000000000001263.
[3]	ZHOU F, ZHOU JH, WANG WX, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70( 4): 1119- 1133. DOI: 10.1002/hep.30702.
[4]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
[5]	WANG YL, LIU JR, LIU J. Research progress on the role of intestinal immune axis in nonalcoholic fatty liver disease[J]. J Shanxi Med Univ, 2023, 54( 4): 554- 560. DOI: 10.13753/j.issn.1007-6611.2023.04.021. 王玉玲, 刘建荣, 刘俊. 肠肝免疫轴在非酒精性脂肪性肝病中作用的研究进展[J]. 山西医科大学学报, 2023, 54( 4): 554- 560. DOI: 10.13753/j.issn.1007-6611.2023.04.021.
[6]	SHARPTON SR, AJMERA V, LOOMBA R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: From composition to function[J]. Clin Gastroenterol Hepatol, 2019, 17( 2): 296- 306. DOI: 10.1016/j.cgh.2018.08.065.
[7]	LI CZ, HUANG XW, ZHANG ZP, et al. Research progress in role of gut-liver axis in occurrence and development of atherosclerosis[J]. J Jilin Univ(Med Ed), 2023, 49( 6): 1669- 1676. DOI: 10.13481/j.1671-587X.20230636. 李朝政, 黄晓巍, 张泽鹏, 等. 肠-肝轴在动脉粥样硬化发生发展中作用的研究进展[J]. 吉林大学学报(医学版), 2023, 49( 6): 1669- 1676. DOI: 10.13481/j.1671-587X.20230636.
[8]	SHENG TJ, YAN SM, LAN WR, et al. Research progress on the influence of intestinal microorganisms on inflammatory bowel disease[J]. Clin J Med Off, 2023, 51( 9): 904- 907. DOI: 10.16680/j.1671-3826.2023.09.06. 盛天骄, 闫思蒙, 兰威儒, 等. 肠道微生物对炎症性肠病影响研究进展[J]. 临床军医杂志, 2023, 51( 9): 904- 907. DOI: 10.16680/j.1671-3826.2023.09.06.
[9]	LIU YY, TAN YY, HUANG JQ, et al. Revealing the mechanism of Huazhi Rougan Granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology[J]. Front Pharmacol, 2022, 13: 875700. DOI: 10.3389/fphar.2022.875700.
[10]	BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology, 2016, 63( 3): 764- 775. DOI: 10.1002/hep.28356.
[11]	CHANG Y, LI H. The role of gut microbiota in the development and progression of nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2018, 34( 6): 1343- 1346. DOI: 10.3969/j.issn.1001-5256.2018.06.045. 常越, 李海. 肠道菌群与非酒精性脂肪性肝炎发生发展的关系[J]. 临床肝胆病杂志, 2018, 34( 6): 1343- 1346. DOI: 10.3969/j.issn.1001-5256.2018.06.045.
[12]	MENG YN, ZHANG YW, ZHANG XY, et al. Regulation of intestinal flora in rats with nonalcoholic steatohepatitis by Xiaoyao Powder[J]. Acta Med Univ Sci Technol Huazhong, 2023, 52( 4): 517- 524. DOI: 10.3870/j.issn.1672-0741.2023.04.013. 孟雅楠, 张玉伟, 张馨月, 等. 逍遥散调节非酒精性脂肪性肝炎模型大鼠肠道菌群的研究[J]. 华中科技大学学报(医学版), 2023, 52( 4): 517- 524. DOI: 10.3870/j.issn.1672-0741.2023.04.013.
[13]	LI HS, XI YF, HE ZY. Preventive and therapeutic effects of HJJB Formula on non-alcoholic steatohepatitis in mice and its influence on intestinal bacteria[J]. China J Tradit Chin Med Pharm, 2022, 37( 10): 6014- 6018. 李红山, 奚瑛斐, 何哲耘. 中药组分HJJB方对小鼠非酒精性脂肪性肝炎的防治作用及其对肠道菌群的影响[J]. 中华中医药杂志, 2022, 37( 10): 6014- 6018.
[14]	JIAN CF, ZHANG BY, WANG CP, et al. Study on the mechanism of Tibetan medicine Wuwei Songshi Wan in regulating intestinal microbiota and improving non-alcoholic steatohepatitis[J]. Chin J Tradit Chin Med, 2022, 47( 8): 2038- 2048. DOI: 10.19540/j.cnki.cjcmm.20211117.707. 简程芳, 张博宇, 王存萍, 等. 藏族药二十五味松石丸调控肠道菌群改善非酒精性脂肪性肝炎的作用机制研究[J]. 中国中药杂志, 2022, 47( 8): 2038- 2048. DOI: 10.19540/j.cnki.cjcmm.20211117.707.
[15]	GUO XX, HU N, LIAN XX, et al. Features of intestinal flora imbalance in patients with liver cirrhosis and related driving factors[J]. J Clin Hepatol, 2020, 36( 7): 1527- 1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016. 郭晓霞, 胡娜, 廉晓晓, 等. 肝硬化患者肠道菌群失调的特征及驱动因子分析[J]. 临床肝胆病杂志, 2020, 36( 7): 1527- 1533. DOI: 10.3969/j.issn.1001-5256.2020.07.016.
[16]	GUO XX, YE YA, LI XK, et al. Changes in the structure of intestinal flora and its clinical significance during the evolution of traditional Chinese medicine syndromes of liver cirrhosis[J]. Chin J Integr Tradit West Med Liver Dis, 2022, 32( 12): 1066- 1072. DOI: 10.3969/j.issn.1005-0264.2022.012.004. 郭晓霞, 叶永安, 李小科, 等. 肝硬化患者中医证型演变过程中肠道菌群结构变化及其临床意义[J]. 中西医结合肝病杂志, 2022, 32( 12): 1066- 1072. DOI: 10.3969/j.issn.1005-0264.2022.012.004.
[17]	ZHENG RP, WANG GQ, PANG ZQ, et al. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma[J]. Cancer Med, 2020, 9( 12): 4232- 4250. DOI: 10.1002/cam4.3045.
[18]	ZHANG SQ, LIN BL. Gut microbiota in patients with liver cirrhosis[J]. J Pract Hepatol, 2023, 26( 3): 313- 316. DOI: 10.3969/j.issn.1672-5069.2023.03.003. 张绍全, 林炳亮. 肠道菌群与肝硬化研究进展[J]. 实用肝脏病杂志, 2023, 26( 3): 313- 316. DOI: 10.3969/j.issn.1672-5069.2023.03.003.
[19]	CAO CF, ZHANG XM, LI XC, et al. The relationship between changes in gut microbiota and HBV-DNA levels in patients with hepatitis B cirrhosis[J]. Chin J Microbiol, 2022, 34( 12): 1436- 1440, 1447. DOI: 10.13381/j.cnki.cjm.202212013. 曹春芳, 张晓曼, 李新才, 等. 乙型肝炎肝硬化患者肠道菌群改变与HBV-DNA水平的关系[J]. 中国微生态学杂志, 2022, 34( 12): 1436- 1440, 1447. DOI: 10.13381/j.cnki.cjm.202212013.
[20]	KONTUREK P, HARSCH I, KONTUREK K, et al. Gut-liver axis: How do gut bacteria influence the liver?[J]. Med Sci, 2018, 6( 3): 79. DOI: 10.3390/medsci6030079.
[21]	REN Z, LI A, JIANG J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellullar carcinoma[J]. Gut, 2019, 68( 6): 1014- 1023. DOI: 10.1136/gutjnl-2017-315084.
[22]	JIANG RY, LAN QY, WANG W, et al. Effects of spleen qi deficiency and inflammatory state on intestinal flora of hepatoma bearing mice and the intervention effect of Jianpi Yiqi Formula[J]. China J Tradit Chin Med Pharm, 2023, 38( 1): 341- 347. 蒋锐沅, 蓝巧玉, 王伟, 等. 脾气亏虚和炎症状态对肝癌荷瘤小鼠肠道菌群的影响及健脾益气方的干预作用[J]. 中华中医药杂志, 2023, 38( 1): 341- 347.
[23]	ZHOU WB, ZHENG Y, SHANG J, et al. Intestinal microecology in mice bearing diethylnitrosamineinduced primary hepatocellular carcinoma[J]. J Zhejiang Univ Med Sci, 2022, 51( 4): 438- 453. DOI: 10.3724/zdxbyxb-2022-0283. 周文斌, 郑越, 尚佳, 等. 二乙基亚硝胺诱导肝细胞癌模型鼠肠道微生态研究[J]. 浙江大学学报(医学版), 2022, 51( 4): 438- 453. DOI: 10.3724/zdxbyxb-2022-0283.
[24]	XIN HR, LI X, SUN RF, et al. Endotoxin and intestinal microflora in patients with hepatocellular carcinoma[J]. Chin J Gen Surg, 2019, 34( 8): 686- 688. DOI: 10.3670.cma.j.issn.1007-631X.2019.08.011.
[25]	HE ZJ, ZHU Q, ZENG L, et al. Research progress in pathogenesis, prevention and treatment of non-alcoholic fatty liver disease[J]. Health Educ Health Promot, 2021, 16( 3): 273- 277, 286. DOI: 10.16117/j.cnki.31-1974/r.202103273. 何卓俊, 朱琪, 曾立, 等. 非酒精性脂肪肝病的发病机制及防治研究[J]. 健康教育与健康促进, 2021, 16( 3): 273- 277, 286. DOI: 10.16117/j.cnki.31-1974/r.202103273.
[26]	ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72( 3): 558- 577. DOI: 10.1016/j.jhep.2019.10.003.
[27]	TRIPATHI A, DEBELIUS J, BRENNER DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 7): 397- 411. DOI: 10.1038/s41575-018-0011-z.
[28]	LU QH, STAPPENBECK TS. Local barriers configure systemic communications between the host and microbiota[J]. Science, 2022, 376( 6596): 950- 955. DOI: 10.1126/science.abo2366.
[29]	MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: A review of the literature[J]. Int J Mol Sci, 2019, 20( 2): 395. DOI: 10.3390/ijms20020395.
[30]	ZHU HF, WU GL. Research progress of nonalcoholic fatty liver disease and intestinal microecology[J/OL]. Chin J Liver Dis(Electron Version), 2013, 5( 4): 77- 80. DOI: 10.3969/j.issn.1674-7380.2013.04.019. 朱洪芳, 吴广利. 非酒精性脂肪性肝病与肠道微生态的研究进展[J/OL]. 中国肝脏病杂志(电子版), 2013, 5( 4): 77- 80. DOI: 10.3969/j.issn.1674-7380.2013.04.019.
[31]	CUI Y, WANG Q, CHANG R, et al. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota[J]. J Agric Food Chem, 2019, 67( 10): 2754- 2762. DOI: 10.1021/acs.jafc.9b00080.
[32]	NICOLETTI A, PONZIANI FR, BIOLATO M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation[J]. World J Gastroenterol, 2019, 25( 33): 4814- 4834. DOI: 10.3748/wjg.v25.i33.4814.
[33]	KAUSHAL K, AGARWAL S, SHARMA S, et al. Demonstration of gut-barrier dysfunction in early stages of non-alcoholic fatty liver disease: A proof-of-concept study[J]. J Clin Exp Hepatol, 2022, 12( 4): 1102- 1113. DOI: 10.1016/j.jceh.2022.01.006.
[34]	WAHLSTRÖM A, KOVATCHEVA-DATCHARY P, STÅHLMAN M, et al. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X receptor signalling[J]. Dig Dis, 2017, 35( 3): 246- 250. DOI: 10.1159/000450982.
[35]	XI YF, LI HS. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease[J]. Biomed Pharmacother, 2020, 121: 109609. DOI: 10.1016/j.biopha.2019.109609.
[36]	JACOB JS, AHMED A, CHOLANKERIL G. The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease[J]. Curr Opin Infect Dis, 2021, 34( 5): 477- 482. DOI: 10.1097/QCO.0000000000000759.
[37]	CARICILLI AM, SAAD MJA. The role of gut microbiota on insulin resistance[J]. Nutrients, 2013, 5( 3): 829- 851. DOI: 10.3390/nu5030829.
[38]	CHEON SY, SONG J. Novel insights into non-alcoholic fatty liver disease and dementia: Insulin resistance, hyperammonemia, gut dysbiosis, vascular impairment, and inflammation[J]. Cell Biosci, 2022, 12( 1): 99. DOI: 10.1186/s13578-022-00836-0.
[39]	SAMUEL BS, SHAITO A, MOTOIKE T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41[J]. Proc Natl Acad Sci USA, 2008, 105( 43): 16767- 16772. DOI: 10.1073/pnas.0808567105.
[40]	TURNBAUGH PJ, LEY RE, MAHOWALD MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest[J]. Nature, 2006, 444( 7122): 1027- 1031. DOI: 10.1038/nature05414.
[41]	XIONG YM, MIYAMOTO N, SHIBATA K, et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41[J]. Proc Natl Acad Sci USA, 2004, 101( 4): 1045- 1050. DOI: 10.1073/pnas.2637002100.
[42]	LI HS, FENG Q, HU YY, et al. Mechanism of qushi Huayu Decoction in improving metabolism of free fatty acid in fatty liver rats[J]. J Tradit Chin Med, 2010, 51( 3): 262- 264. DOI: 10.13288/j.11-2166/r.2010.03.042. 李红山, 冯琴, 胡义扬, 等. 祛湿化瘀方改善脂肪肝大鼠游离脂肪酸代谢的机制[J]. 中医杂志, 2010, 51( 3): 262- 264. DOI: 10.13288/j.11-2166/r.2010.03.042.
[43]	ZHU Y, HE XM, CHEN M, et al. Therapeutic effect of Jiangzhi Decoction on non-alcoholic fatty liver disease and its effect on intestinal flora and metabolism for patient[J]. Chin J Mod Appl Pharm, 2022, 39( 17): 2250- 2256. DOI: 10.13748/j.cnki.issn1007-7693.2022.17.013. 朱彧, 何学敏, 陈明, 等. 降脂方对非酒精性脂肪肝的治疗效果及其对患者肠道菌群和代谢的影响[J]. 中国现代应用药学, 2022, 39( 17): 2250- 2256. DOI: 10.13748/j.cnki.issn1007-7693.2022.17.013.
[44]	MENG XJ, GUO X, ZHANG J, et al. Acupuncture on ST36, CV4 and KI1 suppresses the progression of methionine- and choline-deficient diet-induced nonalcoholic fatty liver disease in mice[J]. Metabolites, 2019, 9( 12): 299. DOI: 10.3390/metabo9120299.
[45]	CHEN XL, TANG CL, XIE H, et al. Effect of electro- acupuncture on hepatic Toll- like receptor 4 and nuclear factor κB expressions in rats with non-alcoholic fatty liver disease[J]. J South Med Univ, 2014, 34( 11): 1584- 1588. DOI: 10.3969/j.issn.1673-4254.2014.11.06. 陈晓琳, 唐成林, 谢辉, 等. 电针对非酒精性脂肪性肝病大鼠肝TLR4、NF-κB表达的影响[J]. 南方医科大学学报, 2014, 34( 11): 1584- 1588. DOI: 10.3969/j.issn.1673-4254.2014.11.06.
[46]	WANG Q, AN SG, WANG WC, et al. Effect of Wangzao Heye Tiaozhi Decoction combined with acupoint application in the treatment of non-alcoholic fatty liver disease(phlegm-stasis interaction type) and its effect on serum SOD and MDA[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 2): 114- 117. DOI: 10.3969/j.issn.1005-0264.2023.002.005. 王倩, 安颂歌, 王文川, 等. 王枣荷叶调脂汤联合穴位贴敷治疗痰瘀互结型非酒精性脂肪性肝病疗效及对血清SOD、MDA的影响[J]. 中西医结合肝病杂志, 2023, 33( 2): 114- 117. DOI: 10.3969/j.issn.1005-0264.2023.002.005.
[47]	WANG Q, AN SG, GUO CJ, et al. Observations on the therapeutic effect of self developed Huoxue Xiaozhuo Fang(Huoxue Xiaozhuo Fang) combined with acupoint application in the treatment of non-alcoholic fatty liver disease(phlegm stasis type)[J]. Chongqing Med J, 2019, 51( 10): 1683- 1686. DOI: 10.3969/j.issn.1671-8348.2022.10.013. 王倩, 安颂歌, 郭慈娟, 等. 自拟活血消浊方溻渍联合穴位贴敷治疗非酒精性脂肪性肝病(痰瘀互结型)的疗效观察[J]. 重庆医学, 2022, 51( 10): 1683- 1686. DOI: 10.3969/j.issn.1671-8348.2022.10.013.
[48]	WANG Q, TENG JY, YAO M, et al. Therapeutic effect of acupoint catgut embedding on simple obesity with phlegm-dampness constitution complicated with nonalcoholic fatty liver[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30( 5): 457- 459. DOI: 10.3969/j.issn.1005-0264.2020.05.024. 王芹, 滕金艳, 姚敏, 等. 穴位埋线治疗痰湿体质单纯性肥胖合并非酒精性脂肪肝的疗效[J]. 中西医结合肝病杂志, 2020, 30( 5): 457- 459. DOI: 10.3969/j.issn.1005-0264.2020.05.024.
[49]	YANG W, ZHOU XL, LIU J, et al. Clinical curative effect exploration of non-alcoholic fatty liver disease of moisture turbidity stopping type treat with catgut implantation based on the infrared thermal imaging technology[J]. J Liaoning Univ Tradit Chin Med, 2019, 21( 5): 118- 122. DOI: 10.13194/j.issn.1673-842x.2019.05.031. 杨薇, 周晓玲, 刘静, 等. 基于医用红外热成像技术评价穴位埋线对湿浊内停型非酒精性脂肪性肝病临床疗效观察[J]. 辽宁中医药大学学报, 2019, 21( 5): 118- 122. DOI: 10.13194/j.issn.1673-842x.2019.05.031.
[50]	XUN DD. Clinical Study on the Treatment of Non-alcoholic Fatty Liver Disease by Moxibustion with Power of Regulating Lipid Metabolism and Soothing Liver[D]. Jinan: Shandong University of Traditional Chinese Medicine, 2018. 荀丹丹. 调脂疏肝灸治疗非酒精性脂肪肝的临床研究[D]. 济南: 山东中医药大学, 2018.
[51]	OZATO N, SAITO S, YAMAGUCHI T, et al. Blautia genus associated with visceral fat accumulation in adults 20-76 years of age[J]. NPJ Biofilms Microbiomes, 2019, 5( 1): 28. DOI: 10.1038/s41522-019-0101-x.
[52]	LUO YH, PENG HW, WRIGHT AD G, et al. Broilers fed dietary vitamins harbor higher diversity of cecal bacteria and higher ratio of Clostridium, Faecalibacterium, and Lactobacillus than broilers with no dietary vitamins revealed by 16S rRNA gene clone libraries[J]. Poult Sci, 2013, 92( 9): 2358- 2366. DOI: 10.3382/ps.2012-02935.
[53]	KE T, TANG YH, HE JY, et al. Effects of Huazhi Fugan Granule on gastrointestinal function and intestinal microflora in mice with diabetic nonalcoholic fatty liver disease[J]. Clin Res Pract, 2023, 8( 13): 5- 8, 37. DOI: 10.19347/j.cnki.2096-1413.202313002. 柯婷, 唐颖慧, 何瑾瑜, 等. 化脂复肝颗粒对糖尿病非酒精性脂肪性肝病小鼠胃肠功能及肠道菌群的影响[J]. 临床医学研究与实践, 2023, 8( 13): 5- 8, 37. DOI: 10.19347/j.cnki.2096-1413.202313002.
[54]	ZHAO ZY, WANG J, REN W, et al. Effect of Jiangan-Jiangzhi pill on gut microbiota and chronic inflammatory response in rats with non-alcoholic fatty liver[J]. Chem Biodivers, 2022, 19( 5): e202100987. DOI: 10.1002/cbdv.202100987.
[55]	WANG HY, WANG Q, LIANG CM, et al. Acupuncture improved hepatic steatosis in HFD-induced NAFLD rats by regulating intestinal microbiota[J]. Front Microbiol, 2023, 14: 1131092. DOI: 10.3389/fmicb.2023.1131092.
[56]	MAI JY, GAO YQ, CAI Z, et al. Influence of Shenge Decoction on intestinal barrier injury and expression of tight junction protein Occludin in intestinal mucosa in rats with non-alcoholic steatohepatitis[J]. Chin J Integr Tradit West Med Liver Dis, 2016, 26( 4): 228- 230, 258. DOI: 10.3969/j.issn.1005-0264.2016.04.014. 麦静愔, 高月求, 蔡峥, 等. 参葛方对非酒精性脂肪性肝炎大鼠肠道黏膜屏障损伤和紧密连接蛋白Occludin表达的影响[J]. 中西医结合肝病杂志, 2016, 26( 4): 228- 230, 258. DOI: 10.3969/j.issn.1005-0264.2016.04.014.
[57]	MA YJ, YU SL, LI QQ, et al. Schisandrin B improves non-alcoholic fatty liver disease by impacting intestinal mucosal barrier function[J]. Acta Pharm Sin, 2021, 56( 10): 2802- 2808. DOI: 10.16438/j.0513-4870.2021-0305. 马钰捷, 余生兰, 李琴琴, 等. 五味子乙素通过增强肠道黏膜屏障功能改善小鼠非酒精性脂肪性肝病的研究[J]. 药学学报, 2021, 56( 10): 2802- 2808. DOI: 10.16438/j.0513-4870.2021-0305.
[58]	LIU KL, ZHANG Q, LI JH, et al. Drug pair of Chaihu(bupleuri Radix) and Renshen(ginseng Radix et rhizoma) for nonalcoholic fatty liver disease via regulating bile acid metabolism[J]. Chin Arch Tradit Chin Med, 2022, 40( 3): 101- 106, 267. DOI: 10.13193/j.issn.1673-7717.2022.03.024. 刘凯利, 张强, 李军辉, 等. 柴胡人参药对通过调控胆汁酸代谢防治非酒精性脂肪肝的研究[J]. 中华中医药学刊, 2022, 40( 3): 101- 106, 267. DOI: 10.13193/j.issn.1673-7717.2022.03.024.